AR081219A1 - Preparacion de clorhidrato de ezatiostat cristalino ansolvatado forma d - Google Patents

Preparacion de clorhidrato de ezatiostat cristalino ansolvatado forma d

Info

Publication number
AR081219A1
AR081219A1 ARP110101769A ARP110101769A AR081219A1 AR 081219 A1 AR081219 A1 AR 081219A1 AR P110101769 A ARP110101769 A AR P110101769A AR P110101769 A ARP110101769 A AR P110101769A AR 081219 A1 AR081219 A1 AR 081219A1
Authority
AR
Argentina
Prior art keywords
ansolvatated
preparation
crystalline ezatiostat
chlorhydrate
crystalline
Prior art date
Application number
ARP110101769A
Other languages
English (en)
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/041,136 external-priority patent/US20120165260A2/en
Application filed by Telik Inc filed Critical Telik Inc
Publication of AR081219A1 publication Critical patent/AR081219A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un procedimiento para preparar ansolvato de clorhidrato de ezatiostat cristalino forma D, que comprende cristalizar clorhidrato de ezatiostat a partir de una solución que comprende etanol y acetato de etilo, bajo condiciones que proveen ansolvato de clorhidrato de ezatiostat cristalino, forma D.
ARP110101769A 2010-06-07 2011-05-24 Preparacion de clorhidrato de ezatiostat cristalino ansolvatado forma d AR081219A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35237710P 2010-06-07 2010-06-07
US46074510P 2010-09-10 2010-09-10
US46074610P 2010-11-12 2010-11-12
US13/041,136 US20120165260A2 (en) 2010-06-07 2011-03-04 Crystalline ezatiostat hydrochloride ansolvate

Publications (1)

Publication Number Publication Date
AR081219A1 true AR081219A1 (es) 2012-07-04

Family

ID=44318209

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101769A AR081219A1 (es) 2010-06-07 2011-05-24 Preparacion de clorhidrato de ezatiostat cristalino ansolvatado forma d

Country Status (7)

Country Link
US (1) US8841476B2 (es)
EP (1) EP2576592A1 (es)
JP (1) JP2013528214A (es)
CN (1) CN102939300A (es)
AR (1) AR081219A1 (es)
TW (1) TW201144260A (es)
WO (1) WO2011156061A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103025753A (zh) * 2010-06-07 2013-04-03 泰立克公司 晶体盐酸依泽替米贝非溶剂化物
US9084176B2 (en) * 2012-06-29 2015-07-14 At&T Intellectual Property I, L.P. Long term evolution network admission management

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5114003A (en) 1991-03-28 1992-05-19 E. I. Du Pont De Nemours And Company Tablet vial with desiccant in bottom
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5955432A (en) 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
ATE297945T1 (de) 1998-04-16 2005-07-15 Teijin Ltd Glutathionderivate und dazugehörige dosisformen
KR20020071931A (ko) * 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
US20040208924A1 (en) 2001-04-26 2004-10-21 Sprockel Omar Leopold Pharmaceutical tablet having a high api content
US7029695B2 (en) * 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2005065639A2 (en) 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
CN101133020A (zh) * 2004-12-03 2008-02-27 特瓦制药工业有限公司 依泽替米贝多晶型
BRPI0606520A2 (pt) 2005-01-06 2009-06-30 Telik Inc tripeptìdeo e tetrapeptìdeo tioéteres
ATE460934T1 (de) 2006-07-19 2010-04-15 Tabuk Pharmaceutical Mfg Co Pharmazeutische zubereitungen von ciprofloxacin
EP2125715A2 (en) 2007-01-24 2009-12-02 Krka Process for the preparation of ezetimibe and derivatives thereof
US20100056493A1 (en) 2007-01-25 2010-03-04 Rajesh Jain Modified release pharmaceutical composition and a process of making the same
RU2010109408A (ru) 2007-08-13 2011-09-20 Панацея Биотек Лимитед (In) Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos

Also Published As

Publication number Publication date
TW201144260A (en) 2011-12-16
EP2576592A1 (en) 2013-04-10
US8841476B2 (en) 2014-09-23
CN102939300A (zh) 2013-02-20
WO2011156061A1 (en) 2011-12-15
US20110301376A1 (en) 2011-12-08
JP2013528214A (ja) 2013-07-08

Similar Documents

Publication Publication Date Title
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
HUE042945T2 (hu) Kvetiapin zsírsav-konjugátumai, eljárás ugyanannak elkészítésére és felhasználására
MX343620B (es) Forma polimorfica de clorhidrato de pridopidina.
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
MY156630A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
IN2012DN04868A (es)
MY150014A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
WO2012176214A3 (en) Process for bendamustine hydrochloride
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
ECSP13012459A (es) Valsartan altamente cristalino
AR081219A1 (es) Preparacion de clorhidrato de ezatiostat cristalino ansolvatado forma d
MY145611A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
JO2854B1 (en) A new method for the synthesis of anfabradine and its added salts with acid is pharmaceutically acceptable.
EA201301136A2 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
UA116994C2 (uk) Стабілізована аморфна форма агомелатину, спосіб її одержання і фармацевтичні композиції, які її містять
WO2012159981A3 (en) PROCESS FOR THE PREPARATION OF α-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS
MY170662A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
JO3276B1 (ar) طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا.
MX2013002990A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
PL2607354T3 (pl) Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem farmaceutycznie dopuszczalnym
BR112013023249A2 (pt) processo para a preparação de acetato de etila
MX337787B (es) Proceso para la sintesis de sal colina de diclofenaco.
SG165255A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid

Legal Events

Date Code Title Description
FB Suspension of granting procedure